活体药物敏感性测试预测了晚期卵巢癌的治疗结果
Kathrin B Labrosse1,2, Flavio C Lombardo1, Ewelina M Bartoszek3
1Department of Biomedicine, Ovarian Cancer Research, University Hospital Basel and University of Basel, Basel, Switzerland.
NPJ precision oncology
|February 6, 2026
概括
这项研究介绍了DRUGSENS,这是一个新的平台,用于表皮卵巢癌 (EOC) 的ex vivo药物测试. 它通过预测患者对治疗的反应来帮助个性化治疗,改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 翻译医学是一种翻译医学.
- 生物技术是生物技术.
背景情况:
- 由于经常复发,高级上皮卵巢癌 (EOC) 的管理具有挑战性.
- 个性化治疗策略对于改善患者的治疗结果至关重要.
- 功能性ex vivo药物测试提供了一种基于个体瘤敏感性的量身定制治疗方法.
研究的目的:
- 介绍DRUGSENS,一个可扩展和临床适应性的体外药物查平台.
- 量化评估EOC细胞系和患者样本中的单细胞,向药物效应.
- 通过分析药物反应和组合来指导个性化治疗决策.
主要方法:
- 药物感应平台使用基于免疫光的共聚焦成像和计算分析 (QuPath,斐济,R包).
- 半自动化测试评估对单个药物和药物组合的反应.
- 来自17名化学疗法原始和复发的EOC患者的21个样本的分析.
主要成果:
- 实现了100%的培养成功,结果在10天内交付.
- 在大多数样本中确定了多药性耐药性,对多种药物的敏感性有限.
- 证明了ex vivo药物反应和无进展/总生存时间之间的显著相关性.
结论:
- 药物感应器为EOC提供了快速,临床相关的功能概况.
- 该平台可以为治疗建议提供信息,并优先考虑临床应用的药物.
- 这个工具支持个性化医疗方法在卵巢癌治疗.
相关概念视频
Predicting Reaction Outcomes
10.9K
Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.9K
Sensitivity, Specificity, and Predicted Value
1.4K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
1.4K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Drugs for Treatment of Constipation-Predominant IBS
859
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
859
Drugs for Treatment of Ulcerative Colitis in IBD
527
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
527
Drugs for Treatment of Diarrhea-Predominant IBS
725
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
725


